| 产品描述: | JNJ-17203212 is a selective, potent and competitive TRPV1 antagonist. JNJ-17203212 is developed for researching pain management, such as migraine |
| 靶点: |
TRPV1 |
| 体内研究: |
JNJ-17203212 (0.3 mg/kg; i.v.) dose-dependently reduces inflammatory soup (IS)-induced the immediate early gene c-fos expression. JNJ-17203212 completely blocks capsaicin-induced CGRP (the neurotransmitter calcitonin gene-related peptide) release in a dose-dependent manner. Animal Model: Male Sprague-Dawley rats (260-300 g) Dosage: 0.3 mg/kg Administration: Intravenous injection Result: Had a dose-dependent effect on the elevated c-fos expression that occurred after intracisternal injection of IS. |
| 参考文献: |
1. Xingjuan Chen, et al. Furanocoumarins are a novel class of modulators for the transient receptor potential vanilloid type 1 (TRPV1) channel.J Biol Chem. 2014 Apr 4; 289(14): 9600-9610. 2. Jannis E Meents, et al. Two TRPV1 receptor antagonists are effective in two different experimental models of migraine. J Headache Pain. 2015; 16: 57. |
| 溶解性: |
Soluble in DMSO |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.387 ml |
11.933 ml |
23.866 ml |
| 5 mM |
0.477 ml |
2.387 ml |
4.773 ml |
| 10 mM |
0.239 ml |
1.193 ml |
2.387 ml |
| 50 mM |
0.048 ml |
0.239 ml |
0.477 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |